JP Morgan Maintains Overweight on Edwards Lifesciences, Raises Price Target to $105
JP Morgan analyst Robbie Marcus maintains Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $100 to $105.
Read original at benzingaStocks · News reference
$100 Invested In Edwards Lifesciences 15 Years Ago Would Be Worth This Much Today
Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 15 years by 1.31% on an annualized basis producing an average annual return of 15.06%. Currently, Edwards Lifesciences has a market capitalization
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 13, 2026, 9:45 PM
- Checked
- Aug 13, 2026, 9:45 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Piper Sandler Reiterates Overweight on Edwards Lifesciences, Raises Price Target to $101
Piper Sandler analyst Adam Maeder reiterates Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $100 to $101.
Read original at benzingaEdwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Says
Edwards Lifesciences tops Q2 Wall Street estimates with $1.74B in revenue. EW stock jumps as analysts see continued upside ahead.
Read original at benzingaEdwards Lifesciences shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance.
Read original at benzinga